Combined Analysis of the Prospective Studies

A secondary, combined analysis of the ARG-911, ARG-915, and ARG-915X studies evaluated the effect of argatroban versus historical control on thrombosis-related (rather than all-cause) outcomes in clinically diagnosed HIT (Lewis et al., 2006). The analysis population included 882 patients (697 argatroban-treated and 185 historical controls), presenting with either HIT or HITTS. The primary endpoint was a 37-day composite of death due to thrombosis, amputation secondary to HIT-associated thrombosis, or new thrombosis.

Argatroban therapy, compared with control, significantly reduced the risk for the thrombotic composite in HIT (hazard ratio, 0.33; 95% CI, 0.20 to 0.54;

TABLE 3 Cox Proportional Hazard Analysis of Argatroban-Treated Patients Versus Historical Control: Combined Data from ARG-911 and ARG-915/X

HIT HIT with thrombosis

TABLE 3 Cox Proportional Hazard Analysis of Argatroban-Treated Patients Versus Historical Control: Combined Data from ARG-911 and ARG-915/X

HIT HIT with thrombosis

Outcome

Hazard ratio (95% CI)

0 0

Post a comment